Background <p>Intratumoral vaccines offer a promising avenue in cancer immunotherapy by harnessing the tumor microenvironment to stimulate immune responses. However, challenges persist in maximizing their effectiveness and addressing immune suppression within tumors.</p> Methods <p>Conventional in situ vaccine (CisVac) and α-CD137 antibody were administered in implanted mouse models of lung and colon cancer to evaluate therapeutic efficacy. The initiation mechanism of…
In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses
Journal for ImmunoTherapy of Cancer | | Wang, M., Qiu, L., Tang, C., Huang, D., Zheng, Q., Li, Z., Zhang, Z., Wei, S., Chen, L., Huang, H., Liu, J., Zhou, J., Lu, T., Liu, G., Nie, Y., Leng, Q., Chen, T.
Topics: colorectal-cancer, blood-cancer, cervical-cancer, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer